2016-03-05T00:00:00.000-05:00
metabolic diseases,-0.783624
pharmaceutical company,-0.55202
Mutual Fund Advisers,0.414285
strong buy rating,0.406204
John A. Orwin,-0.214113
stock,0.139702
consensus price target,0.439832
Equities research analysts,-0.353426
InvestorPlace Broker Center,0.555736
Fund Advisers Trust,0.414285
nonabsorbed polymeric drugs,-0.55202
biopharmaceutical company,-0.567456
research report,0.218565
abnormally elevated levels,-0.712283
Emerald Mutual Fund,0.414285
sell rating,0.363818
Zacks Investment Research,0.320511
personal trading style,0.598412
average rating,-0.253646
Emerald Advisers,0.285163
Relypsa Inc Daily,0.470406
average price,-0.277062
consensus estimate,0.219679
shares,0.0809181
polymeric drugs,-0.559738
non-absorbed polymeric drugs,-0.567456
concise daily summary,0.530175
stock broker,0.245696
company,-0.0581672
Relypsa,-0.017134
Relypsa stock,-0.214113
rating,0.0721676
quarterly earnings data,-0.242644
quarter,0.117562
